source
- Eli Lilly teams with Amplitude on taRNA vaccine platform as Otsuka ends psychedelic trialEli Lilly announced a collaboration with Amplitude Therapeutics to co‑develop vaccine candidates using a trans‑amplifying RNA (taRNA) platform. The taRNA approach aims to boost antigen expression…
- Pheast Therapeutics sticks with open R&D despite competitor Antengene moving ahead with anti‑CD24 trialsPheast Therapeutics, a Redwood City biotech founded in 2021, builds on Irv Weissman’s 2019 Nature paper that highlighted the CD24 protein as a promising "don’t eat me" target for cancer immunothera…